PHILADELPHIA — The investigational drug verekitug improved sinonasal symptoms, reduced nasal polyp size, and reduced the need for nasal polyp surgery in people with chronic rhinosinusitis with nasal ...

Dupilumab yields rapid reductions in nasal polyp burden and improvements in smell function; these benefits persist with extended dosing intervals.

Nasal polyps are soft, painless growths in your sinuses or nasal passages. They are usually benign (noncancerous). Most nasal polyps form from chronic inflammation linked to allergies, asthma, ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Nasal polyps are benign growths often linked to chronic rhinosinusitis. Larger polyps can cause congestion, infections, and reduced smell. Surgery (polypectomy) removes polyps, but they often grow ...

Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP), its second indication after severe asthma. The anti-TSLP antibody has ...

This guidance updates and replaces NICE technology appraisal guidance on dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal; TA648). Next review: This guidance will ...

This recommendation is not intended to affect treatment with dupilumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue ...

One of the most bothersome things about being sick or having seasonal allergies is that it makes your nose stuffy and blocked ...